Navigation Links
Codexis Names Peter Strumph SVP, Commercial Operations
Date:6/28/2010

REDWOOD CITY, Calif., June 28 /PRNewswire-FirstCall/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Peter Strumph has joined the company as Senior Vice President, Commercial Operations, a new position.  Mr. Strumph will be responsible for Codexis pharmaceutical product management and manufacturing operations worldwide.  He will report to Joseph Sarret, M.D., Chief Business Officer and President, Pharmaceutical Services and Enzyme Products.  

Mr. Strumph joins Codexis with twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry. He was Chief Executive Officer of Nile Therapeutics, a cardiovascular company, from 2007-2009.  Previously, he held operations leadership positions for ten years at CV Therapeutics, most recently serving as Senior Vice President, Operations.  At CVT, he oversaw all CMC (chemistry, manufacturing and controls), quality and operations functions. He also held senior operations and manufacturing management roles at Biogen, and staff and manufacturing roles at Bio-Rad Laboratories and Bayer Pharmaceuticals.  Mr. Strumph holds a Bachelor's degree in Systems Science and Engineering and an MBA from the University of Pennsylvania.  

"We are very pleased to welcome Peter Strumph to our management team," Dr. Sarret said.  "He brings Codexis extensive manufacturing management experience, with a focus on commercializing pharmaceuticals products. His breadth of experience in managing successful global pharmaceuticals operations will enable us to better serve our expanding customer base."

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. 

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Derick Sutton, derick.sutton@codexis.com, 650-421-8130


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
2. Codexis, Inc. Announces Pricing of Initial Public Offering
3. Codexis Expands Pharmaceutical Manufacturing Partnerships
4. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Codexis Expands Collaboration with Teva
6. Codexis Names Fernando Valle Research Fellow
7. Gentris Corporation Names New Chief Executive Officer
8. Medical Device and Diagnostic Industry Names Envoy Medical a Company to Watch
9. Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
10. Aveta Inc. Names Josh Valdez President of MSO of Puerto Rico, Inc.
11. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  Ethicon, Inc. today ... Inc., a privately held medical device company that ... Management System, a novel minimally invasive device for ... Torax Medical will enable Ethicon to offer patients ... laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
(Date:2/17/2017)...  Perrigo Company plc (NYSE, TASE: PRGO) today announced it ... Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg ... cough in adults and children 6 years of age and ... were approximately $16 million.   ...
Breaking Medicine Technology:
(Date:2/17/2017)... NC (PRWEB) , ... February 17, 2017 , ... Smiles ... Commons Shopping Center in Davidson, NC. Dr. Brian Seese leads the practice as a ... dental services under one roof. Smiles by Seese serves patients of all ages with ...
(Date:2/17/2017)... Ocala, FL (PRWEB) , ... February 17, 2017 ... ... of software tools that allow for the electronic prescribing of controlled and non-controlled ... , Ninety percent of pharmacies in the United States now accept electronic ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Carol Francis' goals for each and every seminar, session and class she ... demonstrate five different brainwave tools which help energize creativity, focus mental functions, enhance ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today announced that ... Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will be the ... patient signatures solution in healthcare . , Since it first introduced Electronic ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):